Tirzepatide in MetALD | MicrobiomeTrials← Back to trialsNCT07046819
Tirzepatide in MetALD
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-11Est. Completion: 2026-07-30
Enrollment target: 120 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Non-alcoholic Fatty Liver Disease (NAFLD)Alcoholic Liver Disease (ALD)Liver Fibrosis
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the…
Angers, FranceEst. completion Jun 13, 2026
HepatoCellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death…
Multiple LocationsEst. completion Nov 30, 2027